jounce.png
Jounce Therapeutics to Present Preclinical Data from JTX-8064 Program at the 2021 American Association for Cancer Research Virtual (AACR) Annual Meeting
10 mars 2021 16h30 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics Announces Pricing of $56.25 Million Public Offering of Common Stock
09 mars 2021 22h17 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics Announces Proposed Offering of Common Stock
09 mars 2021 16h01 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
25 févr. 2021 06h30 HE | Jounce Therapeutics, Inc.
- Commenced enrollment in both the Phase 1 INNATE trial of JTX-8064 (LILRB2 / ILT4) and the Phase 2 SELECT trial of Vopratelimab in combination with JTX-4014 - - Ended 2020 with $213.2 million in...
jounce.png
Jounce Therapeutics to Present at Upcoming Investor Conferences in March
23 févr. 2021 08h00 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Thursday, February 25, 2021
18 févr. 2021 08h00 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics Appoints Luisa Salter-Cid, Ph.D., to its Board of Directors
12 févr. 2021 08h00 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and PD-1 Inhibitor Combination Therapy in Patients with Advanced Solid Tumors
13 janv. 2021 08h00 HE | Jounce Therapeutics, Inc.
- INNATE is a robust Phase 1 study designed to dose escalate quickly and demonstrate proof of concept for JTX-8064 monotherapy and PD-1i combinations - - Tumor-specific expansion cohorts to...
jounce.png
Jounce Therapeutics to Present at Upcoming Investor Conferences in January
08 janv. 2021 08h00 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics Added to NASDAQ Biotechnology Index
16 déc. 2020 08h00 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...